Literature DB >> 11719266

Anterior cingulate cortical transplantation in transgenic Huntington's disease mice.

A van Dellen1, R Deacon, D York, C Blakemore, A J Hannan.   

Abstract

Huntington's disease (HD) is an autosomal dominant disorder involving progressive neurodegeneration of the corpus striatum and cerebral cortex. Transgenic mice, in which exon 1 of the human HD gene with an expanded trinucleotide repeat is expressed, develop a neurodegenerative syndrome that closely models human HD. Transplantation of wild-type donor cortex into the anterior cingulate cortex of neonatal HD mice (R6/1 line) was found to delay the onset of a specific motor deficit, rear-paw clasping. However, transplantation did not significantly enhance motor performance on a suspended horizontal rod, a behavioural measure of fine motor co-ordination. Control experiments in which the anterior cingulate cortex was resected, but no donor cortical tissue was transplanted, showed no behavioural benefit. In fact, wild-type littermate mice that also underwent this surgical resection, were found to develop motor deficits similar to those exhibited by non-resected HD mice. These results suggest that the anterior cingulate cortex is an important area of pathology in this HD model, and that therapeutic approaches to HD may need to target cortical, as well as striatal areas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719266     DOI: 10.1016/s0361-9230(01)00655-4

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  12 in total

Review 1.  Neural transplantation in patients with Huntington's disease.

Authors:  Anne E Rosser; Stephen B Dunnett
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

3.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Vasanth Pappu; Bruce Fischl; Doug Greve; Nathanael Hevelone; Steven M Hersch
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

4.  Levels of error processing in Huntington's disease: a combined study using event-related potentials and voxel-based morphometry.

Authors:  Christian Beste; Carsten Saft; Carsten Konrad; Jürgen Andrich; Anne Habbel; Inga Schepers; Andreas Jansen; Bettina Pfleiderer; Michael Falkenstein
Journal:  Hum Brain Mapp       Date:  2008-02       Impact factor: 5.038

Review 5.  The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.

Authors:  Julie Leegwater-Kim; Jang-Ho J Cha
Journal:  NeuroRx       Date:  2004-01

Review 6.  Cell therapy in Huntington's disease.

Authors:  Stephen B Dunnett; Anne E Rosser
Journal:  NeuroRx       Date:  2004-10

Review 7.  The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.

Authors:  Jia Yi Li; Natalija Popovic; Patrik Brundin
Journal:  NeuroRx       Date:  2005-07

8.  Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta.

Authors:  Zachary C Baquet; Paula C Bickford; Kevin R Jones
Journal:  J Neurosci       Date:  2005-06-29       Impact factor: 6.167

Review 9.  Genetic and environmental factors in the pathogenesis of Huntington's disease.

Authors:  Anton van Dellen; Anthony J Hannan
Journal:  Neurogenetics       Date:  2004-01-24       Impact factor: 2.660

Review 10.  Spinocerebellar ataxias caused by polyglutamine expansions: a review of therapeutic strategies.

Authors:  Benjamin R Underwood; David C Rubinsztein
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.